tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NLS Pharmaceutics Reschedules Shareholders’ Meeting Amid SEC Review

Story Highlights
NLS Pharmaceutics Reschedules Shareholders’ Meeting Amid SEC Review

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

NLS Pharmaceutics ( (NLSP) ) has shared an update.

On August 21, 2025, NLS Pharmaceutics announced the rescheduling of its Extraordinary Shareholders’ Meeting to September 16, 2025, to allow more time for evaluating comments from the U.S. SEC regarding its pending merger with Kadimastem Ltd. This delay aims to ensure shareholders have the most complete information for decision-making, reflecting the company’s commitment to transparency and regulatory compliance.

More about NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a pharmaceutical company based in Zurich, Switzerland, focusing on the development of therapeutics for the treatment of central nervous system disorders.

Average Trading Volume: 259,628

Technical Sentiment Signal: Sell

Current Market Cap: $9.46M

Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1